Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection

Biomedical Chromatography

Volumn 27, Issue 1, 2013, Pages 122-129

  Burdett, Thomas C ^a   Desjardins, Cody A ^a   Logan, Robert ^a   Mcfarland, Nikolaus R ^b   Chen, Xiqun ^a   Schwarzschild, Michael A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Biological specimens; Electrochemical detection; HPLC; Purines; UV vis detection

Indexed keywords

BIOMOLECULES; BODY FLUIDS; BRAIN; CHEMICAL DETECTION; METABOLISM; METABOLITES; POSITIVE IONS; TISSUE;

BIOLOGICAL SPECIMENS; BRAIN TISSUE; ELECTROCHEMICAL DETECTION; GUANOSINES; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; INOSINE; METABOLIC PATHWAYS; PURINE; UV DETECTION; UV-VIS DETECTION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADENOSINE; DRUG METABOLITE; GUANINE; HYPOXANTHINE; INOSINE; PURINE; XANTHINE;

ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN LEVEL; BRAIN TISSUE; COST BENEFIT ANALYSIS; COULOMETRY; DIAGNOSTIC ACCURACY; DRUG DETERMINATION; ELECTROCHEMICAL DETECTION; ELECTRODE; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; MOUSE; NONHUMAN; PURINE METABOLISM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 84871169787     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2760     Document Type: Article

References (23)

1. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I. Schwarzschild MA and Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson disease. Archives of Neurology 2009; 66(12): 1460-1468.
2. Bakay B, Nissinen E and Sweetman L. Analysis of radioactive and nonradioactive purine bases, nucleosides, and nucleotides by high-speed chromatography on a single column. Analytical Biochemistry 1978; 86(1): 65-77.
3. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nature Reviews. Drug Discovery 2008; 7: 575-590.
4. Cipriani S, Chen X and Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomarkers in Medicine 2010; 4(5): 701-712.
5. Gomez G and Sitkovsky MV. Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood 2003; 102(13): 4472-4478.
6. Iriyama K, Yoshiura M, Iwamoto T and Ozaki Y. Simultaneous determination of uric and ascorbic acids in human serum by reversed-phase high-performance liquid chromatography with electrochemical detection. Analytical Biochemistry 1984; 141(1): 238-243.
7. Irwin N, Li Y, O'Toole JE and Benowitz LI. Mst3b, a purine-sensitive Ste20-like protein kinase, regulates axon outgrowth. Proceedings of the National Academy of Science USA 2006; 103(48): 18320-18325.
8. LeWitt P, Schultz L, Auinger P, Lu M and the Parkinson Study Group DATATOP Investigators. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. Brain Research 2011; 1408: 88-97.
9. Liu Z, Li T and Wang E. Simultaneous determination of guanine, uric acid, hypoxanthine and xanthine in human plasma by reversed-phase high-performance liquid chromatography with amperometric detection. Analyst 1995; 120(8): 2181-2184.
10. Marklund N, Ostman B, Nalmo L, Persson L and Hillered L. Hypoxanthine, uric acid and allantoin as indicators of in vivo free radical reactions. Description of a HPLC method and human brain microdialysis data. Acta Neurochirurgica (Wien) 2000; 142(10): 1135-41; discussion 1141-1142.
11. Nissinen E. Analysis of purine and pyrimidine bases, ribonucleosides, and ribonucleotides by high-pressure liquid chromatography. Analytical Biochemistry 1980; 106(2): 497-505.
12. Quinlan GJ, Lamb NJ, Tilley R, Evans TW and Gutteridge JM. Plasma hypoxanthine levels in ARDS: implications for oxidative stress, morbidity, and mortality. American Journal of Respiratory and Critical Care Medicine 1997; 155(2): 479-484.
13. Ryba M. Reversed-phase liquid column chromatography of pyrimidine and purine derivatives. Journal of Chromatography 1981; 219: 245-254.
14. Schmidt AP, Lara DR and Souza DO. Proposal of a guanine-based purinergic system in the mammalian central nervous system. Pharmacological Therapy 2007; 116(3): 401-416.
15. Schwarzschild MA, Agnati L, Fuxe K, Chen JF and Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends in Neuroscience 2006; 29(11): 647-654.
16. Smolenski RT, Lachno DR, Ledingham SJ and Yacoub MH. Determination of sixteen nucleotides, nucleosides and bases using high-performance liquid chromatography and its application to the study of purine metabolism in hearts for transplantation. Journal of Chromatography 1990; 527(2): 414-420.
17. Stone TW. Adenosine, neurodegeneration and neuroprotection. Neurological Research 2005; 27(2): 161-168.
18. Stover JF, Lowitzsch K and Kempski OS. Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases. Neuroscience Letters 1997; 238(1-2): 25-28.
19. Struck W, Waszczuk-Jankowska M, Kaliszan R and Markuszewski MJ. The state-of-the-art determination of urinary nucleosides using chromatographic techniques 'hyphenated' with advanced bioinformatic methods. Analytical and Bioanalytical Chemistry 2011; 401(7): 2039-2050.
20. Takahashi T, Otsuguro K, Ohta T and Ito S. Adenosine and inosine release during hypoxia in the isolated spinal cord of neonatal rats. British Journal of Pharmacology 2010; 161(8): 1806-1816.
21. Wynants J and Van Belle H. Single-run high-performance liquid chromatography of nucleotides, nucleosides, and major purine bases and its application to different tissue extracts. Analytical Biochemistry 1985; 144(1): 258-266.
22. Zakaria M and Brown PR. High-performance liquid chromatography of nucleotides, nucleosides and bases. Journal of Chromatography 1981; 226(2): 267-290
23. Zitnanová I, Korytár P, Aruoma OI, Sustrová M, Garaiová I, Muchová J, Kalnovicová T, Pueschel S and Duracková Z. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? Clinica Chimica Acta 2004; 341(1-2): 139-146.